Literature DB >> 28324644

Synthesis of T-705-Ribonucleoside and T-705-Ribonucleotide and Studies of Chemical Stability.

Johanna Huchting1, Matthias Winkler1, Hiba Nasser1, Chris Meier1.   

Abstract

T-705 (favipiravir) is a fluorinated hydroxypyrazine carboxamide that exhibits antiviral activities against a variety of RNA viruses. Given the lack of potent agents to combat these infections caused by a large number of high-impact pathogens, significant emphasis has been put on studies of the antiviral properties of T-705 and its mechanism of action. T-705 acts as a nucleobase analogue; it is therefore metabolized to the corresponding ribonucleoside triphosphate intracellularly. Herein we report a reliable synthesis of T-705-ribonucleoside as well as its 5'-monophosphate. Moreover, we disclose detailed studies on the remarkable lability of the heterocycle when attached to ribose under very mild conditions, as typically applied in biochemical studies.
© 2017 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  T-705; antiviral agents; favipiravir; nucleosides; pyrazine ribonucleosides

Mesh:

Substances:

Year:  2017        PMID: 28324644     DOI: 10.1002/cmdc.201700116

Source DB:  PubMed          Journal:  ChemMedChem        ISSN: 1860-7179            Impact factor:   3.466


  9 in total

1.  Pharmacological approaches to the treatment of COVID-19 patients.

Authors:  Lawrence C Sowers; Lucas S Blanton; Scott C Weaver; Randall J Urban; Charles P Mouton
Journal:  J Transl Sci       Date:  2020-04-17

2.  Favipiravir - a Modern Antiviral Drug: Synthesis and Modifications.

Authors:  Yulia A Titova; Olga V Fedorova
Journal:  Chem Heterocycl Compd (N Y)       Date:  2020-07-16       Impact factor: 1.277

3.  Preliminary investigation of drug impurities associated with the anti-influenza drug Favipiravir - An insilico approach.

Authors:  S Anil Kumar; B L Bhaskar
Journal:  Comput Theor Chem       Date:  2021-07-17       Impact factor: 1.926

Review 4.  Nucleosides for the treatment of respiratory RNA virus infections.

Authors:  Paul C Jordan; Sarah K Stevens; Jerome Deval
Journal:  Antivir Chem Chemother       Date:  2018 Jan-Dec

5.  Rapid incorporation of Favipiravir by the fast and permissive viral RNA polymerase complex results in SARS-CoV-2 lethal mutagenesis.

Authors:  Ashleigh Shannon; Barbara Selisko; Nhung-Thi-Tuyet Le; Johanna Huchting; Franck Touret; Géraldine Piorkowski; Véronique Fattorini; François Ferron; Etienne Decroly; Chris Meier; Bruno Coutard; Olve Peersen; Bruno Canard
Journal:  Nat Commun       Date:  2020-09-17       Impact factor: 14.919

6.  Favipiravir and Its Structural Analogs: Antiviral Activity and Synthesis Methods.

Authors:  I D Konstantinova; V L Andronova; I V Fateev; R S Esipov
Journal:  Acta Naturae       Date:  2022 Apr-Jun       Impact factor: 2.204

7.  Favipiravir strikes the SARS-CoV-2 at its Achilles heel, the RNA polymerase.

Authors:  A Shannon; B Selisko; Ntt Le; J Huchting; F Touret; G Piorkowski; V Fattorini; F Ferron; E Decroly; C Meier; B Coutard; O Peersen; B Canard
Journal:  bioRxiv       Date:  2020-05-15

8.  Novel Nucleoside Analogues as Effective Antiviral Agents for Zika Virus Infections.

Authors:  Marcella Bassetto; Cecilia M Cima; Mattia Basso; Martina Salerno; Frank Schwarze; Daniela Friese; Joachim J Bugert; Andrea Brancale
Journal:  Molecules       Date:  2020-10-20       Impact factor: 4.411

Review 9.  A comprehensive update on the structure and synthesis of potential drug targets for combating the coronavirus pandemic caused by SARS-CoV-2.

Authors:  Prerna Malik; Sonika Jain; Pankaj Jain; Jyoti Kumawat; Jaya Dwivedi; Dharma Kishore
Journal:  Arch Pharm (Weinheim)       Date:  2022-01-17       Impact factor: 4.613

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.